Romiplostim for Prevention of Severe Chemotherapy-Induced Thrombocytopenia in Lymphoma Patients—Phase I Study

Cancers 2026 Open access

Read full text
Authors: Erel Joffe, Zachary D. Epstein‐Peterson, Lorenzo Falchi, Ariela Noy, Andrew D. Zelenetz, C. Owens, Leah Gilbert, Gilles Salles, Gerald A. Soff
DOI: 10.3390/cancers18020188
Cited by: 2
References: 19

Abstract

Background/Objectives: Intensive chemotherapy is the cornerstone of lymphoma treatment but often leads to severe chemotherapy-induced thrombocytopenia (sCIT), resulting in treatment delays, reduced dose intensity, and the need for transfusions. While granulocyte colony-stimulating factors (G-CSFs) are commonly used to manage neutropenia, the use of thrombopoietic growth factors has not been adequately studied. Methods: This phase I dose-finding study evaluated the use of weekly romiplostim as prophylaxis for recurrent sCIT in patients undergoing chemotherapy for lymphoma. Eligible patients were those treated with a 21-day chemotherapy cycle who previously experienced sCIT, thus serving as their own “controls”. sCIT was defined as one of the following: (A) a platelet count (PLT)

Fields of Study & Subjects

Neutropenia and Cancer Infections Platelet Disorders and Treatments Blood disorders and treatments

Publication details

Journal / source
Cancers
Publisher
MDPI AG
Volume
18
Issue
2
Pages
188–188
Publication date
6 January 2026
Language
EN